Cosentyx approval tops 2023 hidradenitis suppurativa news

Key takeaways:

• The FDA’s approval of Cosentyx was the most read Healio Dermatology story about hidradenitis suppurativa this year.
• Studies concerning how to treat women with hidradenitis suppurativa were also included.

The FDA’s approval of Cosentyx leads Healio Dermatology’s most read articles this year about hidradenitis suppurativa.

Following Cosentyx’s (secukinumab) FDA approval are stories about new data presented at medical meetings concerning treatments for hidradenitis suppurativa (HS) as well as information about disease management.

Here are five of the most read hidradenitis suppurativa articles on Healio this year:

FDA approves Cosentyx as first IL-17A inhibitor for HS

On Oct. 31, the FDA approved Cosentyx for the treatment of adults with moderate to severe HS, making it the first interleukin-17A inhibitor and second biologic approved for this indication. Read more.

Polycystic ovary syndrome not associated with HS severity

A poster presentation at the American Academy of Dermatology Annual Meeting in New Orleans showed that polycystic ovary syndrome is not associated with increased HS disease severity. However, women with HS are twice as likely to have polycystic ovary syndrome. Read more.

Izokibep shows promise in early phase 2 HS trial

During another presentation at the AAD Annual Meeting, a speaker discussed the results from an early phase 2 study of izokibep, a novel interleukin-17 inhibitor, for the treatment of HS. Results showed that 33% of patients treated with izokibep achieved complete clearance of their HS by week 12. Read more.

Eli Lilly’s novel eltrekibart shows early promise in HS

Eltrekibart, a novel monoclonal antibody that binds to the ligands that signal CXCR1 and CXCR2, may be a promising treatment for HS, according to phase 2 clinical trial results presented at the AAD Annual Meeting. Of the patients taking eltrekibart, 65.6% achieved a 50% improvement in their HS, characterized as a decrease in total abscess and nodule count, after 16 weeks. Read more.

31% of women of childbearing age prescribed teratogenic drugs for HS

According to a study published in the Journal of Drugs in Dermatology, women of childbearing age with HS are often prescribed teratogenic medications with 31% of those women receiving medications that are pregnancy category C or above. Further, 83% of these women also report not receiving physician-led counsel on how HS or medications could impact childbearing. Read more.